Vaxcyte officer plans $82K Rule 144 stock sale

Officer James Wassil filed a Rule 144 notice to sell 1,381 shares of Vaxcyte, Inc. common stock, with recent insider sales also disclosed.

Rhea-AI Filing Summary

Vaxcyte, Inc. (PCVX) is the issuer of common stock that officer James Wassil plans to sell under Rule 144. A notice covers a proposed sale of 1,381 shares through UBS Financial Services Inc., with an aggregate market value of $82,487.13 as of September 4, 2026, on NASDAQ.

The notice also lists prior sales by James Wassil of 2,250 shares on July 1, 2026 for $126,735.98, 2,250 shares on August 3, 2026 for $121,194.45, and 3,477 shares on September 1, 2026 for $212,352.66. The securities to be sold were acquired by RSU vesting on September 2, 2026 from the issuer.

Key Figures

Shares proposed for sale: 1,381 shares Aggregate market value of proposed sale: $82,487.13 Prior sale on July 1, 2026: 2,250 shares for $126,735.98 +3 more

6 metrics

Shares proposed for sale 1,381 shares Common stock covered by the Rule 144 notice through UBS Financial Services Inc.

Aggregate market value of proposed sale $82,487.13 Value of 1,381 shares of Vaxcyte common stock as of September 4, 2026

Prior sale on July 1, 2026 2,250 shares for $126,735.98 Common stock sold by James Wassil during the past three months

Prior sale on August 3, 2026 2,250 shares for $121,194.45 Common stock sold by James Wassil during the past three months

Prior sale on September 1, 2026 3,477 shares for $212,352.66 Common stock sold by James Wassil during the past three months

Acquisition date of RSU shares September 2, 2026 Date 1,381 shares were acquired via RSU vest from Vaxcyte, Inc.

Key Terms

Rule 144, RSU Vest, aggregate market value

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

RSU Vest financial

"Common | 09/02/2026 | RSU Vest | Issuer"

aggregate market value financial

"Common | UBS Financial Services, Inc. ... | 1381 | 82487.13"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

What does the Form 144 filing disclose for Vaxcyte, Inc. (PCVX)?

It discloses that officer James Wassil filed a notice under Rule 144 to potentially sell 1,381 shares of Vaxcyte common stock through UBS Financial Services Inc. with an aggregate market value of $82,487.13 as of September 4, 2026.

How many Vaxcyte (PCVX) shares are covered by the new planned sale?

The notice covers a proposed sale of 1,381 shares of Vaxcyte, Inc. common stock. The aggregate market value stated for these shares is $82,487.13 as of the notice date of September 4, 2026.

What prior Vaxcyte (PCVX) stock sales by James Wassil are listed in the Form 144?

The filing lists sales of 2,250 shares on July 1, 2026 for $126,735.98, 2,250 shares on August 3, 2026 for $121,194.45, and 3,477 shares on September 1, 2026 for $212,352.66.

How were the Vaxcyte (PCVX) shares to be sold acquired by James Wassil?

The shares to be sold, totaling 1,381, were acquired on September 2, 2026 through an RSU vest from the issuer, Vaxcyte, Inc., according to the acquisition information in the filing.

Which broker and market are involved in the Vaxcyte (PCVX) Form 144 sale?

The proposed sale of 1,381 shares of Vaxcyte, Inc. common stock is listed through UBS Financial Services Inc., with the securities indicated for trading on NASDAQ as of the notice dated September 4, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/04/2026 - 04:09 PM Accepted by SEC EDGAR 09/04/2026 - 04:08 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001813798
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Vaxcyte, Inc.
SEC File Number	001-39323
Address of Issuer	825 INDUSTRIAL ROAD, STE. 300 SAN CARLOS CALIFORNIA 94070
Phone	650-837-0111
Name of Person for Whose Account the Securities are To Be Sold	Wassil Jim
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services, Inc. 11 Madison Ave 4th Floor New York NY 10010	1381	82487.13	148805278	09/04/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/02/2026	RSU Vest	Issuer			1381	09/02/2026	NA

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
James Wassil 825 INDUSTRIAL ROAD, STE. 300 SAN CARLOS CA 94070	Common	07/01/2026	2250	126735.98
James Wassil 825 INDUSTRIAL ROAD, STE. 300 SAN CARLOS CA 94070	Common	08/03/2026	2250	121194.45
James Wassil 825 INDUSTRIAL ROAD, STE. 300 SAN CARLOS CA 94070	Common	09/01/2026	3477	212352.66

144: Remarks and Signature

Remarks
Date of Notice	09/04/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	12/09/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ UBS Financial Services Inc, as attorney-in-fact for James Wassil
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)